Refine by
Vaccine Candidate Suppliers & Manufacturers
38 companies found
based inSchlieren, SWITZERLAND
Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards, including the renowned W.A. de Vigier Award. In 2015, Pfizer acquired Redvax (a Redbiotec spin-off) for its ...
Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine ...
based inREDWOOD CITY, CALIFORNIA (USA)
EnGen Bio is developing a therapy and vaccine to provide lifetime immunity to Type A flu. We´ve discovered influenza´s ¨Achille´s heel¨ Unlike conventional flu vaccines, which are generally hemagglutinin or whole-virus based, our vaccine targets a ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
Icosavax has initiated development of IVX-421, a SARS-CoV-2 vaccine candidate that incorporates an RBD antigen with critical mutations found in the SARS-CoV-2 beta ...
based inRedwood City, CALIFORNIA (USA)
Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live ...
Respiratory viruses are one of the biggest threats to human health. Vaccines are the most effective healthcare tool to combat infectious diseases and have saved more lives than any other type of medicine. Meissa is dedicated to ...
based inUlm, GERMANY
Digital health offers, networked testing and vaccination infrastructure solutions. We are there with the vaccination bus and offer the opportunity to have Sars-CoV-2 antibodies determined. The result is delivered digitally as usual, if desired ...
Benefits and core functions of our software solution for covid19 ...
based inSan Carlos, CALIFORNIA (USA)
Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with a unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at scale. We do this by re-engineering how highly complex ...
We believe our clinical-stage company is uniquely positioned to create vaccines that can overcome bacteria’s formidable defense mechanisms and be produced on a significant scale. We are leveraging our XpressCF™ cell-free protein ...
based inOxford, UNITED KINGDOM
Utilising unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide. SpyBiotech came into being to change that. Our pioneering technology, the proprietary protein superglue SpyTag/SpyCatcher, enables us ...
CMV is the most common virus that most people have never heard of, even though it has now been identified as a high priority for vaccines development by key authorities such as the FDA and Institute of ...
based inSaint-Herblain, FRANCE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
Herpes simplex virus-2 (HSV-2) is the leading cause of genital herpes, a sexually transmitted disease affecting over 500 million people worldwide. BlueWillow’s intranasal nanoemulsion (NE) vaccine is uniquely suited to offer protection against ...
based inMadison, WISCONSIN (USA)
FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine ...
The M2 Deleted Single Replication Live Virus Vaccine (M2SR) offers a potentially differentiating clinical value proposition. FluGen’s flu vaccine candidate works differently, stimulating ...
based inLondon, UNITED KINGDOM
Founded in 2015, the original idea behind Airfinity was to systematically capture and structure the new science disseminated at conferences, a highly fragmented dataset. However, through working with medical associations and pharma companies, ...
Informational biosecurity strategies, funding allocations and procurement decisions across defence, health and science ministries. Horizon scanning to pre-empt future health emergencies. In collaboration with a number of ministries across the UK, ...
based inHørsholm, DENMARK
We are an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. We have developed our AI-immunology core technology to deeply understand the biological ...
EDEN is our second AI platform that rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. EDEN has been designed to rapidly identify those antigens that will ...
based inMalvern, PENNSYLVANIA (USA)
Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform ...
based inActon, AUSTRALIA
Lipotek is a developer of targeted vaccine delivery and adjuvant technologies. There is an undeniable need for technological solutions for prophylactic and therapeutic vaccination against pathogens, cancer and other diseases that have limited or no ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
based inWoburn, MASSACHUSETTS (USA)
We are an investigational-stage infectious disease company focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections. Using our proprietary technology, we are developing rationally ...
One of the most celebrated achievements of modern medicine is the eradication of the smallpox virus with the use of a live-attenuated vaccine. We are advancing the applied science of attenuating live viruses to develop an entirely new class of ...
based inUppsala, SWEDEN
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane ...
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune ...
based inSaint Louis, MISSOURI (USA)
Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the ...
based inAalborg Øst, DENMARK
2A Pharma is a clinical stage Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented AAVLP platform. To develop novel, cost ...
The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...